198 related articles for article (PubMed ID: 11051273)
1. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000.
Meyers FJ; O' Donnell RT
Clin Cancer Res; 2000 Oct; 6(10):4167. PubMed ID: 11051273
[No Abstract] [Full Text] [Related]
2. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
[TBL] [Abstract][Full Text] [Related]
4. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
8. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for malignant melanoma.
Stoutenburg JP; Schrope B; Kaufman HL
Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
11. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
[TBL] [Abstract][Full Text] [Related]
12. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
13. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
14. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
16. Of snails and holy grails..
Yang JC
Cancer J Sci Am; 1997; 3(3):142-3. PubMed ID: 9161778
[No Abstract] [Full Text] [Related]
17. Cytokine therapy in advanced melanoma.
Kalaaji AN
J Drugs Dermatol; 2007 Apr; 6(4):374-8. PubMed ID: 17668534
[TBL] [Abstract][Full Text] [Related]
18. [Cytokine therapy for metastatic renal cell carcinoma].
Eto M; Naito S
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
[TBL] [Abstract][Full Text] [Related]
19. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
20. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]